Video
Dr. Schmoll Discusses CHARTA Results in CRC
Author(s):
Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the results of the CHARTA study in colorectal cancer.
Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the results of the CHARTA study in colorectal cancer.
The final results and multivariate prognostic factor analysis of the CHARTA study, which evaluated FOLFOX and bevacizumab (Avastin) with or without irinotecan, were presented at the 2017 World Congress on Gastrointestinal Cancer.
Results showed that FOLFOX and bevacizumab plus irinotecan was superior to FOLFIRI plus bevacizumab, which was reported on previously in the TRIBE study.
